NICE gives limited approval for Darzalex in multiple myeloma.- Janssen.
The National Institute for Health and Care Excellence (NICE) has supported the NHS use of Darzalex (daratumumab), from Janssen, via the Cancer Drugs Fund (CDF) for some adults with previously treated multiple myeloma. NICE�s appraisal committee has announced that it can't be recommended for routine use in treating relapsed and refractory multiple myeloma in adults, due to uncertainties in clinical data, and this means that NICE's estimates of the drugs cost effectiveness are unreliable.
Interim funding through the CDF has been approved by NICE � to treat relapsed and refractory multiple myeloma in adults whose disease has progressed despite three prior treatments, including proteasome inhibitor and an immunomodulator - to allow for the collection of additional data until November 2020, after which guidance will be reviewed.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.